AnaptysBio (NASDAQ:ANAB) Stock Price Down 5.9%

AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) fell 5.9% during trading on Thursday . The stock traded as low as $20.10 and last traded at $20.20. 214,966 shares were traded during trading, a decline of 31% from the average session volume of 311,290 shares. The stock had previously closed at $21.47.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ANAB. Wedbush upgraded AnaptysBio from a "neutral" rating to an "outperform" rating and lifted their target price for the stock from $20.00 to $34.00 in a research note on Tuesday, March 12th. BTIG Research began coverage on AnaptysBio in a research note on Monday, February 26th. They set a "buy" rating and a $55.00 target price for the company. Wells Fargo & Company started coverage on AnaptysBio in a research note on Thursday, April 11th. They set an "overweight" rating and a $56.00 target price for the company. JPMorgan Chase & Co. reduced their price target on AnaptysBio from $30.00 to $28.00 and set a "neutral" rating for the company in a research note on Monday, April 1st. Finally, Piper Sandler started coverage on AnaptysBio in a research note on Friday, February 16th. They issued an "overweight" rating and a $80.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, AnaptysBio presently has an average rating of "Moderate Buy" and an average price target of $46.22.

AnaptysBio Trading Down 7.6 %

The business has a 50-day moving average price of $23.31 and a two-hundred day moving average price of $20.54. The stock has a market capitalization of $530.65 million, a P/E ratio of -3.26 and a beta of -0.30.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its earnings results on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share for the quarter, beating analysts' consensus estimates of ($1.74) by $0.15. AnaptysBio had a negative return on equity of 119.42% and a negative net margin of 953.66%. The firm had revenue of $9.01 million during the quarter, compared to the consensus estimate of $3.28 million. On average, sell-side analysts forecast that AnaptysBio, Inc. will post -6.25 earnings per share for the current fiscal year.

Insider Transactions at AnaptysBio

In other news, CEO Daniel Faga sold 3,000 shares of the business's stock in a transaction on Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now owns 749,087 shares of the company's stock, valued at approximately $16,045,443.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Daniel Faga sold 3,000 shares of the business's stock in a transaction on Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now owns 749,087 shares of the company's stock, valued at approximately $16,045,443.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eric J. Loumeau sold 5,000 shares of the business's stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the transaction, the insider now directly owns 3,240 shares of the company's stock, valued at approximately $81,000. The disclosure for this sale can be found here. In the last quarter, insiders sold 157,005 shares of company stock valued at $3,586,199. Corporate insiders own 35.50% of the company's stock.

Institutional Investors Weigh In On AnaptysBio

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP acquired a new stake in shares of AnaptysBio in the second quarter valued at about $34,000. Allspring Global Investments Holdings LLC bought a new stake in shares of AnaptysBio during the 1st quarter valued at about $38,000. Tower Research Capital LLC TRC boosted its position in shares of AnaptysBio by 248.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,596 shares of the biotechnology company's stock valued at $65,000 after purchasing an additional 2,565 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in shares of AnaptysBio by 350.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company's stock valued at $66,000 after purchasing an additional 2,390 shares in the last quarter. Finally, BNP Paribas Arbitrage SA boosted its position in shares of AnaptysBio by 75.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company's stock valued at $101,000 after purchasing an additional 2,142 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.